Objectives: The objective of the present study was to assess the in vitro and in vivo activities of DW-224a in order to eventually use it as an antibiotic.
Introduction
The quinolones have evolved from agents used only for the treatment of urinary tract infections (UTIs) to the latest fluoroquinolones with a remarkably broad spectrum of activity and excellent pharmacokinetics allowing for once-daily dosing and thus improving patient compliance. 1 These compounds have been prescribed extensively for the treatment of respiratory tract infections, UTIs, sexually transmitted diseases and infections of the skin and soft tissue. 2 However, as use of fluoroquinolones has increased, the continuous increase in the resistance among bacteria is generally recognized. [3] [4] [5] The development of new antibacterial substances thus appears of utmost importance. Actually many different approaches are taken to develop new compounds. The targets in fluoroquinolone research during the past few years include improving the pharmacokinetic properties, increasing the activity against Gram-positive cocci and anaerobes and against fluoroquinolone-resistant strains, and improving activity against non-fermentative Gram-negative species. 1 Several new candidates have been developed in such an attempt by the R&D Center, Dong Wha Pharmaceutical Industry Co., Ltd (Anyang City, Korea). We previously reported that DW286, a novel fluoronaphthyridone antibiotic developed by Dong Wha Pharmaceutical Industry Co., Ltd, exhibited potent in vitro antibacterial activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant S. aureus (QRSA), and the most potent efficacy in experimental systemic mouse models of MRSA and QRSA infections. 5 However, DW286 showed some side effects including genetic toxicity (data not shown).
Another Figure 1 ). In the present study, we investigated the in vitro activity of DW-224a against various clinical isolates in comparison with DW286, ciprofloxacin and trovafloxacin. In addition, the in vivo protective efficacy of DW-224a against systemic infections caused by S. aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli and Klebsiella pneumoniae was evaluated in mice.
Materials and methods

Antimicrobial agents and bacteria
The studied compounds were obtained as follows: DW-224a, DW286 and ciprofloxacin were synthesized at the R&D Center, Dong Wha Pharmaceutical Industry Co., Ltd. Trovafloxacin was provided by Pfizer Pharmaceuticals (New York, NY, USA). Clinical isolates were obtained from hospitals in Seoul, Korea, between 1996 and 2002. The challenge organisms used in the mouse systemic infections were as follows: S. pyogenes ATCC 8668 was obtained from the American Type Culture Collection (Rockville, MD, USA), and S. aureus Smith was kindly provided by Professor S. Goto of Toho University, Tokyo, Japan. E. coli MB4-78, K. pneumoniae MB4-02 and S. pneumoniae MB4-21 were selected through the pathogenicity screening of clinical isolates. 6 
Determination of MICs
Unless otherwise specified, MICs were determined by an agar dilution method with Mueller-Hinton agar (MHA; Difco Laboratories, Detroit, MI, USA) following the Clinical and Laboratory Standards Institute (formerly National Committee for Clinical Laboratory Standards) procedure.
7 Enterococcus faecalis, Enterococcus faecium and S. pyogenes were grown on brain heart infusion (BHI) agar and S. pneumoniae and Haemophilus influenzae were grown on BHI agar supplemented with 1% bactosupplement B (Difco) and 1% Isovitalex (Difco) at 37 C. Test compounds were prepared according to the manufacturers' instructions and diluted in sterilized distilled water and further diluted in the corresponding medium to achieve a concentration range of 0.001-64 mg/L. Agar plates containing test compounds were inoculated with the strains using a microplater (Sakuma, Tokyo, Japan) that delivered 10 4 cfu per spot. The cultures were incubated at 37 C and the MIC determined after 18 h. MIC tests were performed in duplicate.
Determination of the in vivo activity
The study was designed to evaluate the protective effect of the fluoroquinolones in a systemic infection model in mice. The organisms used were S. aureus Smith, S. pyogenes ATCC 8668, S. pneumoniae MB4-21, E. coli MB4-78 and K. pneumoniae MB4-02. The organisms were cultured overnight in BHI broth at 37 C. Male ICR mice (body weight, 18-22 g; age, 4 weeks) were inoculated intraperitoneally with 0.3 mL of a bacterial suspension adjusted with 3% gastric mucin (ICN Biomedicals, Columbus, OH, USA) in saline solution at a dose 100 times higher than the minimal lethal dose. The challenge inoculum was sufficient to kill 100% of the untreated control mice, which died within 48 h after infection. An aliquot of 0.2 mL of each test compound was administered once orally to mice immediately after infection. Five groups of seven mice each were treated with 0.16, 0.63, 2.5, 10 or 40 mg/kg of each antibacterial agent. The 50% protective dose (PD 50 ) was calculated by the method of Reed and Muench 8 from the survival rates on day 7 after infection. All animal experiments were performed in accordance with the guidelines of our Institutional Animal Care and Use Committee.
Results and discussion
In vitro activity
The antibacterial activity of DW-224a against clinical isolates was compared with those of DW286, ciprofloxacin and trovafloxacin ( Table 1 ). The MIC values of the control compounds are comparable to previous results. 5 Antibacterial activity of DW-224a was superior to the activities of ciprofloxacin and trovafloxacin and was slightly inferior to that of DW286 against QRSA and S. pyogenes. DW-224a was also more active than ciprofloxacin, similar to trovafloxacin and inferior to DW286 against QSSA and Staphylococcus epidermidis. Like DW286, DW-224a was more active than ciprofloxacin and comparable to trovafloxacin against E. faecalis and 3-fold more active than ciprofloxacin or trovafloxacin against E. faecium. Against S. pneumoniae, DW286 was most active and DW-224a was more active than ciprofloxacin and similar to trovafloxacin. In general, DW-224a showed potent activity against Gram-positive organisms. Against Gram-negative bacteria, including members of the family Enterobacteriaceae, DW-224a was inferior to ciprofloxacin, but it was as active as trovafloxacin or DW286. The MIC 50 s and MIC 90 s for clinical strains of E. coli, K. pneumoniae, Klebsiella oxytoca, Citrobacter freundii, Enterobacter cloacae, Enterobacter aerogenes, Proteus spp., Providencia stuartii, Morganella morganii, Serratia marcescens, Salmonella spp. and Shigella spp. were 0.031-1 and 0.125-8 mg/L, respectively. The activity of DW-224a against H. influenzae was superior to that of trovafloxacin and similar to the activities of ciprofloxacin and DW286. Against Pseudomonas aeruginosa, DW-224a was less active than ciprofloxacin or trovafloxacin and comparable to DW286. Against Stenatrophomonas maltophilia and Acinetobacter calcoaceticus, the activity of DW-224a was similar to the activities of the other compounds. In summary, in vitro activity of DW-224a against Gram-positive bacteria was higher than the activities of ciprofloxacin and trovafloxacin, but slightly lower than that of DW286. Especially against fluoroquinolone-resistant strains, such as QRSA, E. faecalis and E. faecium, the overall activities of DW-224a were more potent than those of ciprofloxacin and trovafloxacin. Against Gram-negative bacteria, DW-224a showed In vitro and in vivo activities of DW-224a In vitro and in vivo activities of DW-224a activity similar to the activities of trovafloxacin and DW286 and less activity than that of ciprofloxacin. These findings suggest that DW-224a, with increased activities against Gram-positive cocci and fluoroquinolone-resistant strains, yet retaining activity against Gram-negative species, may be very useful for the treatment of clinically significant pathogens, including multidrug-resistant Gram-positive pathogens.
In vivo activity
The therapeutic effects of DW-224a and comparative quinolones against systemic infections in mice are shown in Table 2 . Against S. aureus Smith and S. pneumoniae MB4-21, the in vivo activity of DW-224a was inferior to that of DW286 and comparable to that of trovafloxacin, but considerably better than that of ciprofloxacin. Like DW286, DW-224a showed highest activity against infections with S. pyogenes ATCC 8668, with a PD 50 of 0.26 mg/kg. In infections caused by E. coli MB4-78 and K. pneumoniae MB4-02, the activity of DW-224a was inferior to the activities of ciprofloxacin and trovafloxacin, but similar to that of DW286. In summary, DW-224a showed great in vivo efficacies against Gram-positive organisms, but similar or somewhat inferior activity to those of comparative compounds against Gram-negative bacteria. These results correlated with the in vitro MICs. Based on its in vitro and in vivo efficacy, DW-224a seems to be a promising antibiotic with a broad spectrum of antimicrobial activity, including potent activity against S. pneumoniae and S. pyogenes. Safety pharmacology study of DW-224a was conducted after oral administration of the drug to mice, rats and dogs. 9 DW-224a appears to have exerted no adverse effects on the central nervous, cardiovascular and respiratory systems with the exception of the effect on the QT interval prolongation. After oral administration of the drug to dogs, the absorption of DW-224a was fast;
10 the plasma concentration of DW-224a was detected from the first blood sampling time (0.5 h) and reached its peak within 1-3 h. DW-224a was not accumulated above the toxic dose after the 4 week oral administration. 10 Efficacy and safety or tolerability profile is now being assessed further in Phase I clinical trials to treat various bacterial infections. 
